Kidney-Selective Conjugates for Nephrotoxicity Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for kidney protection against nephrotoxic active compounds, such as cisplatin, carboplatin, and gentamicin, are limited by dose restrictions and side effects like arterial hypotension, highlighting the need for targeted kidney-specific protection methods.
Innovation Solution
Development of conjugates combining kidney-selective carrier molecules with active compounds that can selectively target and protect the kidneys, using peptides and ε-polylysine conjugates to enhance kidney specificity and reduce nephrotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amifostin is administered to protect against nephrotoxicity, then kidney protection is improved, but arterial hypotension occurs as a severe side effect
Solution Approach 1:
The invention segments the protective action by using kidney-selective carrier molecules (such as peptides with specific sequences like APASLYN or HITSLLS, or MAG3-based carriers) to deliver amifostin or similar protective compounds specifically to kidney tissue. This segmentation allows the protective effect to be localized to the kidney while minimizing systemic exposure and side effects like arterial hypotension.
Solution Approach 2:
The kidney-selective carrier molecules act as intermediaries that facilitate the targeted delivery of protective compounds to the kidney. These carriers (including peptide-based carriers, MAG3 conjugates, or other renal-targeting vectors) mediate the transport of the protective agent from systemic circulation into kidney cells, particularly proximal tubule cells, thereby protecting the kidney without causing systemic hypotension.
2Productivity
If higher doses of nephrotoxic active compounds are administered, then therapeutic effect is improved, but nephrotoxic damage increases
Solution Approach 1:
The invention applies preliminary action by administering kidney-selective protective conjugates before the nephrotoxic active compound. The protective agents (such as amifostin, N-acetylcysteine, or other antioxidants/apoptosis inhibitors) are delivered to the kidney in advance, where they prepare the kidney cells for subsequent exposure to the toxic compound by activating defense mechanisms, scavenging reactive oxygen species, and preventing oxidative stress before it occurs.
Solution Approach 2:
The invention converts the nephrotoxic harmful effect into a beneficial outcome by using the same kidney-selective delivery system to administer both the toxic compound and the protective compound. The protective agents, delivered via the same renal-targeting carriers, transform the potentially harmful exposure into a protected state, allowing higher therapeutic doses to be administered safely.
3Measurement precision
If kidney-selective carrier molecules are used to target protective compounds, then specificity to kidney is improved, but systemic protection is reduced
Solution Approach 1:
The invention applies local quality by designing carrier molecules with specific properties that enable selective accumulation in kidney tissue. The carriers (such as peptides containing basic amino acids like lysine and arginine, or MAG3 conjugates) exploit the unique physiology of the kidney, particularly the organic cation transporters and glomerular filtration characteristics, to achieve high local concentration in the kidney while maintaining low concentration in other organs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates achieve high specificity and accumulation in the kidneys, reducing nephrotoxic damage by blocking transport mechanisms, providing antioxidative protection, inhibiting apoptosis, and activating repair mechanisms, thereby minimizing kidney damage during chemotherapy or radiotherapy.
Implementation Method 1
Amifostin itself is a prodrug which is cleaved by alkaline phosphatases located in the membrane of the endothelial cells to give the actual active compound 2-((aminopropyl)amino)ethanethiol.
Implementation Method 2
The conjugates achieve high specificity and accumulation in the kidneys, reducing nephrotoxic damage by blocking transport mechanisms
Implementation Method 3
The active species is the antioxidative thiol group of 2-((aminopropyl)amino)ethanethiol
Data Source
AI summary
The present invention relates to a conjugate containing at least one kidney-selective carrier molecule and at least one active compound which has a protective action for the kidney against nephrotoxic active compounds, to a process for the preparation of the conjugate, to the use thereof for the protection of the kidney against nephrotoxic active compounds, and to a medicament comprising the conjugate.